GlassScriptPhysician profile
Chassie E Harris
NPI 1851636203
$2,371.29
in general payments reported to CMS, 2019-2025
28 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,099 · 2022: $410 · 2023: $301 · 2024: $161 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $778.08 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $235.42 | 2024-2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $215.40 | 2021 | |
| Esperion Therapeutics, INC. | $167.27 | 2021 | |
| Alkermes, INC. | $122.55 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Lilly USA, LLC | $89.30 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.07 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.61 | 2021 | |
| Pfizer INC. | $55.36 | 2021 | |
| Eisai INC. | $51.44 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $50.44 | 2021-2024 | Airsupra |
| Glaxosmithkline, LLC. | $39.96 | 2022-2024 | Arexvy, Shingrix |
| Daiichi Sankyo INC. | $38.57 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.95 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $35.25 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $34.39 | 2021 | |
| Amgen INC. | $28.32 | 2021 | |
| Abbott Laboratories | $27.41 | 2021 | |
| Gilead Sciences, INC. | $26.36 | 2022 | |
| Boston Scientific Corporation | $23.60 | 2025 | Enroute Transcarotid Stent |
| Jazz Pharmaceuticals INC. | $23.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $22.39 | 2021 | |
| Exact Sciences Corporation | $22.02 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $21.52 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.34 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.27 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.24 | 2024 | Horizant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chassie Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.